BACKGROUND: Heterozygous gain-of-function mutations in various genes encoding proteins of the Ras-MAPK signalling cascade have been identified as the genetic basis of Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFCS). Mutations of SOS1, the gene encoding a guanine nucleotide exchange factor for Ras, have been the most recent discoveries in patients with NS, but this gene has not been studied in patients with CFCS. METHODS AND RESULTS: We investigated SOS1 in a large cohort of patients with disorders of the NS-CFCS spectrum, who had previously tested negative for mutations in PTPN11, KRAS, BRAF, MEK1 and MEK2. Missense mutations of SOS1 were discovered in 28% of patients with NS. In contrast, none of the patients classified as having CFCS was found to carry a pathogenic sequence change in this gene. CONCLUSION: We have confirmed SOS1 as the second major gene for NS. Patients carrying mutations in this gene have a distinctive phenotype with frequent ectodermal anomalies such as keratosis pilaris and curly hair. However, the clinical picture associated with SOS1 mutations is different from that of CFCS. These findings corroborate that, despite being caused by gain-of-function mutations in molecules belonging to the same pathway, NS and CFCS scarcely overlap genotypically.
BACKGROUND: Heterozygous gain-of-function mutations in various genes encoding proteins of the Ras-MAPK signalling cascade have been identified as the genetic basis of Noonan syndrome (NS) and cardio-facio-cutaneous syndrome (CFCS). Mutations of SOS1, the gene encoding a guanine nucleotide exchange factor for Ras, have been the most recent discoveries in patients with NS, but this gene has not been studied in patients with CFCS. METHODS AND RESULTS: We investigated SOS1 in a large cohort of patients with disorders of the NS-CFCS spectrum, who had previously tested negative for mutations in PTPN11, KRAS, BRAF, MEK1 and MEK2. Missense mutations of SOS1 were discovered in 28% of patients with NS. In contrast, none of the patients classified as having CFCS was found to carry a pathogenic sequence change in this gene. CONCLUSION: We have confirmed SOS1 as the second major gene for NS. Patients carrying mutations in this gene have a distinctive phenotype with frequent ectodermal anomalies such as keratosis pilaris and curly hair. However, the clinical picture associated with SOS1 mutations is different from that of CFCS. These findings corroborate that, despite being caused by gain-of-function mutations in molecules belonging to the same pathway, NS and CFCS scarcely overlap genotypically.
Authors: Martin Zenker; Katarina Lehmann; Anna Leana Schulz; Helmut Barth; Dagmar Hansmann; Rainer Koenig; Rudolf Korinthenberg; Martina Kreiss-Nachtsheim; Peter Meinecke; Susanne Morlot; Stefan Mundlos; Anne S Quante; Salmo Raskin; Dirk Schnabel; Lars-Erik Wehner; Christian P Kratz; Denise Horn; Kerstin Kutsche Journal: J Med Genet Date: 2006-10-20 Impact factor: 6.318
Authors: Marco Tartaglia; Kamini Kalidas; Adam Shaw; Xiaoling Song; Dan L Musat; Ineke van der Burgt; Han G Brunner; Débora R Bertola; Andrew Crosby; Andra Ion; Raju S Kucherlapati; Steve Jeffery; Michael A Patton; Bruce D Gelb Journal: Am J Hum Genet Date: 2002-05-01 Impact factor: 11.025
Authors: Luciana Musante; Hans G Kehl; Frank Majewski; Peter Meinecke; Susann Schweiger; Gabriele Gillessen-Kaesbach; Dagmar Wieczorek; Georg K Hinkel; Sigrid Tinschert; Maria Hoeltzenbein; Hans-Hilger Ropers; Vera M Kalscheuer Journal: Eur J Hum Genet Date: 2003-02 Impact factor: 4.246
Authors: Yline Capri; Elisabetta Flex; Oliver H F Krumbach; Giovanna Carpentieri; Serena Cecchetti; Christina Lißewski; Soheila Rezaei Adariani; Denny Schanze; Julia Brinkmann; Juliette Piard; Francesca Pantaleoni; Francesca R Lepri; Elaine Suk-Ying Goh; Karen Chong; Elliot Stieglitz; Julia Meyer; Alma Kuechler; Nuria C Bramswig; Stephanie Sacharow; Marion Strullu; Yoann Vial; Cédric Vignal; George Kensah; Goran Cuturilo; Neda S Kazemein Jasemi; Radovan Dvorsky; Kristin G Monaghan; Lisa M Vincent; Hélène Cavé; Alain Verloes; Mohammad R Ahmadian; Marco Tartaglia; Martin Zenker Journal: Am J Hum Genet Date: 2019-05-23 Impact factor: 11.025
Authors: E A Croonen; W Nillesen; C Schrander; M Jongmans; H Scheffer; C Noordam; J M T Draaisma; I van der Burgt; H G Yntema Journal: Mol Syndromol Date: 2013-05-08
Authors: M C Digilio; F Lepri; A Baban; M L Dentici; P Versacci; R Capolino; R Ferese; A De Luca; M Tartaglia; B Marino; B Dallapiccola Journal: Mol Syndromol Date: 2011-09-14